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Available online - - -AbstractBarrett’s oesophagus is a condition which predisposes towards development of oesophageal adenocarcinoma, a highly lethal tumour which
has been increasing in incidence in theWesternworld over the past three decades. There have been tremendous advances in the field of Barrett’s
oesophagus, not only in diagnostic modalities, but also in therapeutic strategies available to treat this premalignant disease. In this review, we
discuss the past, present and future of Barrett’s oesophagus.We describe the historical and new evolving diagnostic criteria of Barrett’s oesoph-
agus, while also comparing and contrasting the British Society of Gastroenterology guidelines, American College of Gastroenterology guide-
lines and International Benign Barrett’s and CAncer Taskforce (BOBCAT) for Barrett’s oesophagus. Advances in endoscopic modalities such
as confocal and volumetric laser endomicroscopy, and a non-endoscopic sampling device, the Cytosponge, are described which could aid in
identification of Barrett’s oesophagus. With regards to therapy we review the evidence for the utility of endoscopic mucosal resection and ra-
diofrequency ablation when coupled with better characterization of dysplasia. These endoscopic advances have transformed the management
of Barrett’s oesophagus from a primarily surgical disease into an endoscopically managed condition.
 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Population studies have suggested that up to 1.6% of Eu-
ropeans have Barrett’s oesophagus (BO), a condition in
which the native squamous epithelial lining of the distal
oesophagus undergoes metaplastic change to a columnar
epithelium due to chronic damage caused by gastro-
oesophageal reflux disease (GORD).1,2 Barrett’s oesophagus
and its predisposing condition, GORD is a major risk factor
for the development of oesophageal adenocarcinoma (OAC),
a highly malignant cancer which has been increasing in the
Western population over the past three decades.3e6
Ever since the relationship between BO and OAC was es-
tablished in the 1970s, there has been a rapid increase in
research activity in the field of BO particularly in its diagnosis
andmanagement. The common goal among investigators is tothor. MRC Cancer Unit, University of Cambridge,
Biomedical Campus, Cambridge CB2 0XZ, United
0)1223763241.
cf29@mrc-cu.cam.ac.uk (R.C. Fitzgerald).
16/j.ejso.2017.02.004
he Authors. Published by Elsevier Ltd. This is an open acc
).
le in press as: Tan WK, et al., Past, present and future of Bcurb the progression of this precancerous condition before
incurable malignancy sets in.7e9 However, with advancing
knowledge has come misconception and controversy, partic-
ularly with regards to the definition and the diagnostic criteria
of BO. Even today there remains no universally adopted defi-
nition of BO among authorities in this field.
In this review, we describe the past, present and future of
BO. We further explore the evolving definition and diag-
nostic criteria of BO and try to understand where there is
consensus and which areas still require resolution. In addi-
tion, we describe developments in therapeutic modalities
and how this has the potential to impact on the mortality
of OAC in the future.
Diagnosis of Barret’s oesophagusHistorical perspective and evolution of the diagnostic
criteria for Barrett’s oesophagusBO bears its name from the pioneering British surgeon,
Norman Barrett who in 1950 published his seminal paper eess article under the CC BY-NC-ND license (http://creativecommons.org/
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tis’’ in which he described the columnar-lined oesoph-
agus.10,11 However, it was Wilder Tileston who first
reported three cases of ‘peptic ulcer of the oesophagus’ in
1906 wherein he described the histology of the ulcer and
adjacent epithelium which resembled a gastric ulcer in
columnar epithelium.12 Over the next four decades, dis-
agreements regarding the distal oesophageal histology
were prevalent, with some arguing that the ulcers in the
distal oesophagus were not oesophageal, but gastric ulcers
within an intrathoracic stomach in patients with congenital
short oesophagus.13e16 In fact, this notion was supported by
Barrett in his paper in 1950.10
In 1953, Allison and Johnstone published an influential
report rejecting Barrett’s hypothesis, and suggesting that
the tubular structure within the distal thorax could not be
stomach since it: 1) lacked an outer peritoneal lining; 2)
had musculature identical to oesophagus; 3) consisted of
columnar epithelium interspersed with squamous islands;
4) lacked mucosal oxyntic cells; and 5) had mucosal glands
typical of the oesophagus.17 Subsequent reassessment of
these ‘gastric’ ulcers by Barrett led him to acknowledge
his prior misjudgement, and he published a revised report
in 1957, redefining this tubular structure as ‘lower oesoph-
agus lined by columnar epithelium’.18
Between 1960 to the mid-1970s, there were varying his-
tological descriptions of the columnar subtypes in the distal
oesophagus including junctional (gastric cardiac epithe-
lium), gastric-fundal, and intestinal epithelium with goblet
cells.19e21 This histologic conundrum was clarified in 1976
by Paull et al., who performed biopsies on 11 patients with
a columnar-lined distal oesophagus and elucidated the pres-
ence of a histologic spectrum which from most proximal to
distal comprised: columnar epithelial containing villi and
goblet cells (now known as intestinal metaplasia, IM and
sometimes referred to as Specialised Intestinal Metaplasia);
followed by junctional epithelium; and finally, atrophic
gastric fundal epithelium with chief and parietal cells.22
In the 1980s it was established that GORD and the pres-
ence of a hiatal hernia were risk factors for BO and it grew
to be appreciated that these could distort the anatomic land-
marks of the GOJ during endoscopy making a precise diag-
nosis difficult.23,24 To avoid error, diagnostic criteria for
BO were established by Skinner et al. who proposed that
a minimum of 3 cm columnar lining is required to diagnose
BO and for enrolment into clinical studies.25 By the mid-
1980s, the association between BO and OAC was well es-
tablished7e9 and it became clear that IM had a mosaic dis-
tribution with strong predisposition to dysplasia which led
to IM becoming the defining feature for BO.26,27
In the mid-1990s, Spechler et al. challenged the conven-
tional practice of only performing biopsies on BO 3 cm
because he demonstrated that 18% of patients with endo-
scopically apparent BO measuring less than 3 cm still con-
tained IM.28 Furthermore, there were reports of OAC
developing from BO <3 cm.29,30 These results, coupledPlease cite this article in press as: Tan WK, et al., Past, present and future of B
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long segments (3 cm) have proved essential in shaping
the diagnostic criteria for BO over the years.31Current diagnostic criteria for Barrett’s oesophagusThe quality of endoscopic images has improved signifi-
cantly with the advent of high resolution endoscopes mak-
ing it easier to discern the landmarks. Today, a diagnosis of
BO requires endoscopic visualization of columnar epithe-
lium 1 cm above the gastro-oesophageal junction (GOJ)
in addition to histological confirmation of columnar
metaplasia.32Endoscopic diagnosis of Barrett’s oesophagusEndoscopy remains the gold standard to diagnose BO.
During endoscopy, three important landmarks need to be
recognized: 1) the GOJ, 2) the diaphragmatic pinch and
3) the squamo-columnar junction (SCJ). The GOJ signals
the end of the oesophagus and the start of the stomach
and is best identified as the most proximal margin of the
gastric folds.33 The diaphragmatic pinch is the point at
which the diaphragmatic crura constricts or ‘pinches’ the
oesophagus and is an important landmark to denote the
presence of a hiatal hernia. The SCJ is the transitional point
between stratified squamous and columnar epithelial of the
stomach. Visually, squamous epithelial has a pale glossy
colour while columnar epithelial adopts a darker reddish
appearance due to its increased vasculature. In normal
oesophagus, the GOJ and SCJ coincide. However, when
the SCJ lies 1 cm above the GOJ at the level of its
most proximal extension, then this suggests the presence
of BO.Histological diagnosis of Barrett’s oesophagusHistologic criteria for BO still remain a contentious
issue. The recent American College of Gastroenterology
(ACG) requires biopsies confirming IM as a pre-requisite
to diagnose BO.34,35 However, the British Society of
Gastroenterology (BSG) guideline stipulates that in the
context of visible columnar epithelium with biopsy confir-
mation, IM is not a pre-requisite and hence gastric meta-
plasia is also regarded as a type of BO32 (Table 1). The
recent International Benign Barrett’s and CAncer Taskforce
(BOBCAT) consensus defines BO as presence of columnar
epithelial but stipulates that it should be clearly stated
whether IM is present above the GOJ.36 The BSG and
ACG difference hinges on the differential risk of malignant
transformation between columnar epithelium with and
without IM. The emphasis on IM as a defining feature of
BO is based on increasing number of studies that have
demonstrated a stronger association between IM and
OAC than non-IM. For example, a study of 8522 patients
with BO reported that the risk for malignant progressionarrett’s oesophagus, Eur J Surg Oncol (2017), http://dx.doi.org/10.1016/
Table 1
Comparison between BSG guidelines, ACG guidelines and BOBCAT consensus in the diagnosis of Barrett’s oesophagus.
Diagnostic feature British Society of Gastroenterology, 201432 American College of Gastroenterology,
201634
International Consensus (BOBCAT),
201536
Definition Endoscopically visible metaplastic columnar
epithelial 1 cm above the GOJ plus biopsy
confirmation of columnar metaplasia
Endoscopically visible metaplastic
columnar epithelial 1 cm above the
GOJ plus biopsy confirmation of IM
Endoscopically visible metaplastic
columnar epithelial 1 cm above the
GOJ, and pathologist should clearly state
whether IM is present on biopsies above
the GOJ
Endoscopic
landmark for
localizing GOJ
Proximal extent of the gastric folds Proximal extent of the gastric folds Proximal extent of the gastric folds
Reporting the
extent of
Barrett’s
oesophagus
Usage of Prague C&M criteria Usage of Prague C&M criteria Usage of Prague C&M criteria
Biopsy Protocol
for suspected
Barrett’s
oesophagus
Random 4 quadrant biopsies every 2 cm plus
biopsy of visible lesions
Random 4 biopsies every 2 cm or 8
random biopsies to maximize IM yield.
For suspected short segment BO where 8
biopsies is unattainable, a minimum of 4
biopsies/cm circumferential extent and 1
biopsy/cm Barrett’s tongue is
recommended
Random 4 quadrant biopsies every 2 cm
plus biopsy of visible lesions
Normal Z line or
Z line <1 cm
from GOJ
Routine biopsy not recommended Routine biopsy not recommended Not discussed
Confirmation of
Dysplasia
Cases of suspected dysplasia need to be
confirmed by a second GI pathologist
Cases of suspected dysplasia need to be
confirmed by a second GI pathologist
Cases of suspected dysplasia need to be
confirmed by a second GI pathologist
Use of p53
biomarker to
aid dysplasia
diagnosis
Should be considered as adjunct to current
diagnostic tools in the diagnosis of dysplasia
Not recommended Not recommended for routine use, but
can be considered as adjunct to aid
diagnosis if done in specialist centres
BSG, British Society of Gastroenterology; ACG, American College of Gastroenterology; BOBCAT; Benign Barrett’s and Cancer Taskforce, GOJ, Gastro-
oesophageal junction; C&M, circumferential and maximum; IM, Intestinal Metaplasia; GI, gastrointestinal.
3W.K. Tan et al. / EJSO xx (2017) 1e13of IM was greater compared to gastric metaplasia (0.38%/
year vs 0.07%/year, hazard ratio, HR ¼ 3.54, 95%
CI ¼ 2.09e6.00, p < 0.01).37 Chandrasoma et al. then
showed that among 214 patients with columnar oesophagus
who had biopsies taken with strict adherence to Seattle pro-
tocol, IM was noted in all patients who had dysplasia or
OAC, while none of the patients with cardiac-type epithe-
lium alone displayed dysplastic features or OAC.38 More
recently, detailed genomic analysis comparing IM and
non-IM epithelium in 45 patients with BO reported a higher
frequency of mutations in cancer-associated genes such as
CDKN2A, WWOX, c-MYC and GATA6 in IM.39
However, other studies have not corroborated such find-
ings. A retrospective analysis of 688 patients reported no
significant difference in cancer risk of IM versus non-
IM.40 However, this study did not provide details regarding
endoscopic findings, and whether those without IM went on
to develop IM during follow-up.40 In another study, Takubo
et al. examined the mucosa adjacent to 141 cases of OAC
resected endoscopically and found >70% of OAC were
lying adjacent to non-IM columnar epithelial, indicating
that non-IM epithelial could also harbour features for ma-
lignancy.41 However, given that IM has a non-uniform dis-
tribution in BO, the extent of the pathological examination
is critical and it is also possible that these cancers could
have originated from the stomach.Please cite this article in press as: Tan WK, et al., Past, present and future of B
j.ejso.2017.02.004The BSG guidelines argues for a broader diagnostic
criteria to encompass columnar metaplasia with or without
IM because IM detection is prone to sampling error and
because understanding of the cellular and molecular basis
for malignant risk continues to evolve.42 The Seattle protocol
which incorporates 4-quadrant biopsies every 1e2 cm pro-
vides a rigorous and reliable method for obtaining adequate
biopsies for BO diagnosis; however, this protocol is not
strictly adhered to in clinical practice. A Dutch study showed
that adherence to the Seattle protocol was 79% for BO up to
5 cm, but decreased to 30% for BO lengths 10e15 cm.43
Similar findings were reported in a large study of 2245 pa-
tients where only 51% of BO diagnosis adhered to the proto-
col.44 In a comparative study designed to determine the
optimal number of oesophageal biopsies for IM, investigators
showed that the diagnostic yield for IM increases with the
number of biopsies.45When the number of biopsies increased
from 4, to 8 and to16, diagnostic accuracy for IM increased
from 34.7% to 67.9% and to 100%, respectively.45 These
conclusions have led to the latest ACG recommendation of
obtaining at least 8 random biopsies on suspected Barrett’s
column during index endoscopy to maximize diagnostic
yield.34 While obtaining 16 biopsies would achieve 100%
accuracy, this would not only be time consuming, but might
also increase the risk of post-biopsy haemorrhage as well as
the increased cost of processing biopsy.arrett’s oesophagus, Eur J Surg Oncol (2017), http://dx.doi.org/10.1016/
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newly publishedEuropean position statement agreeswith the
statements defined here, however, similar to the ACG, it re-
quires IM for diagnosis.35Whilst the BSG guideline includes
all histologically confirmed metaplasia in the definition, the
clinical follow-up for any individual patient is determined by
the risk of cancer progression and aside from dysplasia two
of the strongest risk factors are segment length46,47 and pres-
ence of IM. A recent study by Pohl et al. showed that the
annual risk of cancer progression of long (3 cm), short
(1 to 3 cm) and ultra-short (1 cm) BO varied consider-
ably, with the risk being 0.22%, 0.03% and 0.01%, respec-
tively.46 Hence, for patients with short segments (<3 cm)
without IM, it is recommended that the procedure is repeated
to ensure that there is indeed columnar mucosa within the
oesophagus (and that this has not been mistaken for a hiatus
hernia) and to repeat biopsies for IM. In patients with a short
segment of gastric-type epithelium the risks of surveillance
are thought to outweigh the benefits in view of the low risk
for cancer progression.46 All three guidelines support the
use of the proximal gastric folds as the landmark for delin-
eating the GOJ. Similarly, all three guidelines endorse the
application of the Prague C&M criteria (grading system for
BO according to its circumferential extent (C value, in
cm), and the maximum length of BO tongues (M value, in
cm)) when reporting BO length since it has good inter-
observer reliability (r ¼ 0.72) for BO  1 cm.48Confirmation of dysplasiaDysplasia is a biomarker for cancer risk in BO and is
graded according to the Vienna classification.49 However,
there remains substantial inter-observer variability with re-
gards to the grading of dysplasia between pathologists. In a
Dutch study where two gastrointestinal (GI) pathologists
retrospectively reviewed 293 BO specimens with a prior
diagnosis of lowegrade dysplasia (LGD), only 27% had
‘true’ LGD, while the remaining 73% were downgraded
to non-dysplasia (ND) or indefinite-for-dysplasia (IND).50
Following histologic review, patients with confirmed LGD
were shown to have a higher risk for cancer progression
(9.1%/patient-year) compared to those who were down-
graded to ND (0.6%/patient-year) and IND (0.9%/patient-
year).50 Recently, a study comparing pathologist from the
United States and Europe showed poor inter-observer
agreement when diagnosing LGD (k ¼ 0.11, 95% CI
0.004e0.15).51 As the grading of dysplasia invariably dic-
tates management strategies, unsurprisingly all three guide-
lines require that the diagnosis of dysplasia is confirmed by
two GI pathologists.32,34,36
Histologic confirmation of dysplasia thus remains the
only acceptable predictor for cancer progression; however,
it is prone to sampling bias and high inter-observer vari-
ability. Alternative biomarkers, in particular p53 expression
has emerged as a possible adjunct to improve risk stratifica-
tion of BO. Sikkema et al. showed that p53 proteinPlease cite this article in press as: Tan WK, et al., Past, present and future of B
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sion to high-grade dysplasia (HGD) or OAC irrespective
of histology (HR 6.5; 95% CI 2.5e17.1) compared to a
diagnosis of LGD (HR 3.6; 95% CI 1.6e8.1).52 More
recently, an analysis of >12,000 biopsies from 635 patients
with BO showed that aberrant p53 expression (p53 overex-
pression or loss of p53 expression which can occur with a
truncating mutation of the p53 gene) was associated with
increased cancer risk, and furthermore the risk was higher
for BO with loss of p53 expression (adjusted relative risk,
RRa 14.0, 95% CI 5.3e37.2) compared to BO with p53
overexpression (RRa 5.6, 95% CI 3.1e10.3).53 Further-
more, immunohistochemistry for p53 detection had good
inter-observer reliability.53 Therefore, although p53 stain-
ing has not yet reach mainstream clinical use, its use could
allow more accurate risk stratification of BO into higher
risk groups who will require more intensive surveillance.Future diagnostic strategies for Barrett’s oesophagusTechnologies for diagnosing BO have advanced over the
years with a number of technologies aimed to better char-
acterize dysplasia in secondary care (confocal and volu-
metric laser endomicroscopy). However, whether these
modalities actually increase dysplasia detection has not
been proven. Since the majority of Barrett’s is undiagnosed,
technologies have also been developed for diagnosing BO
more readily in primary care (tethered capsule endomicro-
scopy, transnasal endoscopy and Cytosponge).Confocal Laser EndomicroscopyConfocal Laser Endomicroscopy (CLE) is a powerful
imaging modality that combines endoscopy and micro-
scopy to obtain high resolution and magnified images of
the GI mucosa. CLE comes in the form of a probe-based
system (pCLE) where a probe is passed through a port
within the endoscope. An endoscope-based CLE (eCLE)
previously existed, however, this system is no longer avail-
able on the market. CLE is based on the principle of tissue
illumination by a blue laser (488 nm), with detection of
fluorescence reflecting off tissues aided by the application
of fluorescein which is excited by the laser.54,55 CLE can
achieve subcellular resolution up to 250 mm depth with
500e1000 magnification.56 This permits in-vivo tissue
evaluation at endoscopy and can effectively distinguish
non-dysplastic, dysplastic and neoplastic epithelium.57,58
Trials for pCLE have been promising wherein addition of
pCLE to white light endoscopy (WLE) and narrow band im-
aging (NBI, an endoscopic technology that uses light of
shorter wavelength to allow better visualization of mucosal
abnormalities and vascular patterns associated with
dysplasia)59 have reported increased sensitivity of detection
of neoplasia from 45.0% to 75.8% (p ¼ 0.01).60 Further, the
use of autofluorescence imaging (AFI, a technology that de-
tects abnormal tissue architecture by exploiting fluorescencearrett’s oesophagus, Eur J Surg Oncol (2017), http://dx.doi.org/10.1016/
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dysplasia in real-time (‘optical biopsy’) has been shown to
have a sensitivity of 96.4% sensitivity compared to 57.1%
sensitivity for AFI with NBI.61 While CLE is promising the
interpretation requires specialist training and expertise in
interpretation therefore its use is currently restricted to aca-
demic hospitals. Current work is underway to define criteria
for diagnosing dysplasia that could be adopted across studies.Volumetric laser endomicroscopyOptical coherence tomography (OCT) relies on the prin-
ciple of backscattering of light to produce high resolution
images. A new generation OCT, Volumetric Laser Endomi-
croscopy (VLE) is an emerging technology that incorpo-
rates a rotating optical laser probe centred within a
transparent balloon. A laser (wavelength 1350 nm)
emanating from the probe in a helical fashion, with an auto-
mated pullback, circumferentially scans 6 cm of the distal
oesophagus up to 3 mm depth to produce cross-sectional
images of the oesophagus up to the submucosal layer.62
A case series of 6 patients with long segment BO who un-
derwent both WLE with NBI at index endoscopy, followed-
up by VLE with targeted biopsies within 6 months showed
that VLE led to upstaging of disease status, allowing these
patients to qualify for ablative therapy.63 The requirement
for a gold standard for these studies can lead to difficulty
in determining which is superior.
A tethered-capsule endomicroscopy device has also
been designed which utilises optical frequency domain im-
aging technology to generate 3D, microscopic images of
the oesophageal wall at 30 mm lateral, and 7 mm axial res-
olution.64 The capsule is swallowed and then withdrawn
upon reaching the stomach. During transit, cross-sectional
images of the oesophagus are acquired and the images
are reconstructed to produce a 3D representation of the
entire oesophagus.64 A feasibility study on 7 healthy volun-
teers and 6 volunteers with BO showed that this procedure
is safe whilst also producing high quality subsurface images
that are easily missed on WLE.64
This technology opens up new avenues for BO imaging
as it not only can be used as a screening modality, but could
also detect architectural abnormalities of mucosa and sub-
mucosa which could indicate dysplasia.64 The ease of per-
forming the procedure with minimal training required,
coupled with the ability of the capsule to be disinfected
and reused might make it cost-effective and feasible as a
screening tool in primary care. Although promising, larger
studies assessing the accuracy of VLE imaging and histo-
pathologic correlation are necessary prior to adopting this
technology into routine practice.Transnasal endoscopyFigure 1. The Cytosponge expanded (left) and encapsulated (right). Repro-
duced with permission from Kadri et al.68
Transnasal endoscopy (TNE) has emerged as a possible
alternative to transoral endoscopy for diagnosing BO.Please cite this article in press as: Tan WK, et al., Past, present and future of B
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Vision Sciences) have produced ‘ultrathin’ endoscopes
with a slimmer diameter (5e6 mm) than the standard endo-
scope, whilst also containing a working channel (up to
2 mm diameter) which allows for biopsies. A portable
and disposable transnasal endoscope (E.G. Scan, Intro-
Medic, Seoul, South Korea) has also been developed and
when compared to traditional endoscopy, was shown to
have reasonable level of agreement of detecting BO
(k ¼ 0.617, 95% CI 0.378e0.860).65 More recently, a trans-
nasal endoscope with a disposable sheath (TNE-5000 with
Endosheath, Vision Science, NY, USA) has been developed
which protects the scope from contact with body fluids and
circumvents the need for decontamination. In a pilot cross-
over randomised controlled trial (RCT), Endosheath tech-
nology had a 100% sensitivity and specificity for
obtaining an endoscopic diagnosis of BO, and a 66.7%
and 100% sensitivity and specificity, respectively, for ob-
taining a histologic diagnosis of BO when compared to
transoral endoscopy.66 The advantages of TNE includes:
1) better patient tolerance and acceptability, 2) better safety
profile (no need for sedation) and 3) suitability for use in
primary care (E.G. Scan).66,67 It could also be cost-
effective as it can be performed by technicians after suffi-
cient training and does not require post-procedural vital
sign monitoring.67 Despite its many advantages, limitations
of TNE include failure of intubation (due to narrow nasal
canal) and epistaxis (up to 5%).67 Although transoral
endoscopy remains the standard for upper GI endoscopy,
the many advantages of TNE is a promising tool for BO
screening in primary care. It is not recommended for sur-
veillance as the field of view, image quality and size of bi-
opsies are not optimal for detection of dysplasia.Cytosponge and Trefoil Factor-3The Cytosponge is a cell sampling device that comprises
a small compressed mesh within a gelatin capsule
(Fig. 1).68 The capsule is swallowed and disintegrates
upon reaching the stomach to release a 3 cm-diameter
spherical mesh that is withdraw by pulling the string whicharrett’s oesophagus, Eur J Surg Oncol (2017), http://dx.doi.org/10.1016/
6 W.K. Tan et al. / EJSO xx (2017) 1e13then samples the entire length of the oesophagus, collecting
up to one-million cells.42 Immunohistochemistry for Trefoil
Factor-3 (TFF3), a protein which is over-expressed in BO,
is then performed on paraffin-embedded cytologic speci-
mens as an objective diagnostic biomarker which is scored
as positive or negative.69
The BEST-1 feasibility study evaluated the use of
Cytosponge-TFF3 to diagnose BO and showed that it was
applicable in primary care and although not the primary
outcome, had a promising specificity of 93.8% and sensi-
tivity of 73.3% for detecting BO 1 cm. For segments
2 cm, the specificity and sensitivity were 93.5% and
90.0%, respectively.68 The subsequent BEST-2 study which
enrolled 1110 participants in a case-control design to
enable assessment of sensitivity and specificity, reported
79.9% sensitivity for Cytosponge-TFF3 to detect BO
increasing to 87.2% for BO circumferential segment
3 cm.70 The specificity for BO was 92.4%.70 These fig-
ures are comparable to the current colorectal cancer
screening programme using faecal occult blood test
(FOBT) which has a sensitivity and specificity range of
6.2e83.3% and 65e99%, respectively.71
The BEST-3 study will begin recruitment in early 2017
with the aim of comparing the use of the Cytosponge-TFF3
with standard care (lifestyle advice, acid-suppressing med-
ications and, Helicobacter Pylori eradication) against stan-
dard care alone in patients with reflux disease in the
primary care setting. This study is designed to assess
whether Cytosponge-TFF3 could lead to increased detec-
tion of BO in primary care and to evaluate the health eco-
nomics of this approach. It is hoped that this study will
provide pivotal information regarding the development of
a comprehensive and cost-effective screening programme
for BO.
Therapy for Barrett’s oesophagus
Treatments for BO have evolved considerably over the
past twenty years and have altered the clinical rationale
for detection of Barrett’s. Traditionally, oesophagectomy
was the only option for high-grade dysplasia and carci-
noma; however, with advancing technology, endoscopic
therapy has become the mainstay treatment for BO. We
begin by describing the brief history of oesophagectomy,
followed by discussion on the current (surveillance, radio-
frequency ablation and endoscopic resection) and future
(cryotherapy and chemoprevention) management strategies
for BO.Historical treatment for Barrett’s oesophagus e
oesophagectomyFigure 2. Cryotherapy using the Coldplay cryoballoon system (C2 Thera-
peutics/Pentax Medical).Oesophagectomy still remains the only definitive ther-
apy for invasive OAC. Although surgical outcomes have
improved over the years, oesophagectomy still remains a
challenging procedure as patients often have multiplePlease cite this article in press as: Tan WK, et al., Past, present and future of B
j.ejso.2017.02.004existing co-morbidities and so it is not without risks. The
transthoracic oesophagectomy (Ivor Lewis oesophagec-
tomy, ILO) is considered the gold standard procedure and
was first performed by Ivor Lewis in 1944 on a patient
who had OAC of the distal oesophagus.72 He performed a
laparotomy to mobilize the stomach and a left-sided thora-
cotomy for resecting the oesophagus.72 Although there are
variations to the standard oesophagectomy including a tran-
shiatal approach, the Ivor Lewis procedure is often prefer-
able as it permits better visualization of abdominal contents
and allows for wide margins of lymph node dissection.73
With the success of laparoscopic surgery during the late
1980s, Watson et al. reported two cases of minimally inva-
sive oesophagectomy (MIO) by utilising laparoscopic
means for gastric mobilization, followed by a thoracoscopic
approach for oesophageal resection and anastomosis,
achieving excellent results with shorter hospital stay and
convalescence.74 A recent phase 3 RCT (MIRO trial)
comparing open ILO to MIO reported favourable short-
term outcomes for MIO with lower post-operative
morbidity (37 vs 67, p ¼ 0.0001) and pulmonary complica-
tions (18 vs 31, p ¼ 0.037), but no difference in 30-day
mortality between groups.75 More recently, robotic-ILO is
gaining popularity since it provides magnified images and
better freedom of movement via wristed motions compared
to laparoscopic approach.76 However, more studies are
needed to assess the safety and outcomes of robotic-ILO
compared to open or MIO.Current management for Barrett’s oesophagusSurveillance and endoscopic therapyAlgorithms for the management of flat and nodular BO,
with or without dysplasia are shown (Figs. 3 and 4). Forarrett’s oesophagus, Eur J Surg Oncol (2017), http://dx.doi.org/10.1016/
Figure 3. Algorithm for management of Barrett’s oesophagus with flat mucosa (non-nodular). BO; Barrett’s oesophagus, GI; Gastrointestinal, PPI; Proton
Pump inhibitor, OGD; Oesophagogastroduodenoscopy, IM; Intestinal metaplasia, LGD; Low grade dysplasia, HGD; High grade dysplasia, RFA: Radiofre-
quency ablation, MDT; Multidisciplinary team.
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endoscopic surveillance (Table 2). However, the BOBCAT
consensus does not recommend surveillance, but if surveil-
lance is undertaken, suggests that it should be targeted at
high risk patients stratified according to patient demo-
graphics, BO length, frequency and severity of symptoms
(Table 2). However, there is currently no clinically adopted
algorithm for a risk stratification approach due to paucity of
data and this is an area which requires further research. A
recent paper describes a risk-stratification panel comprising
clinical factors (age, waist-to-hip ratio and BO segment
length) and molecular biomarkers applied to a Cytopsonge
sample (glandular atypia, Aurora Kinase A, and p53). A
risk stratification calculator can then be used to risk stratify
BO with dysplasia.77 Such approaches are promising and as
more data become available, future surveillancePlease cite this article in press as: Tan WK, et al., Past, present and future of B
j.ejso.2017.02.004programme will likely be based upon risk stratification us-
ing biomarkers.
BO is considered indefinite for dysplasia when patholo-
gists are unable to accurately delineate dysplastic features
from inflammatory atypia.78 For such cases, PPI optimiza-
tion with repeat OGD in 6 months is recommended.32 If no
dysplasia is found on follow-up, then surveillance should
follow non-dysplastic BO.
As discussed earlier cases of LGD should be confirmed
by a second GI pathologist with a repeat endoscopy in 6
months. Additionally, the ACG recommends aggressive
PPI for LGD followed by repeat endoscopy in 6 months
since PPI may lead to downgrading of dysplastic status.79
If repeat endoscopy confirms LGD, ablative therapy should
be offered.34 Radiofrequency ablation (RFA) is the ablative
therapy of choice and is performed via a balloon catheterarrett’s oesophagus, Eur J Surg Oncol (2017), http://dx.doi.org/10.1016/
Figure 4. Algorithm for management of Barrett’s oesophagus with endoscopically visible nodular lesion. *Data for management of LGD with nodular lesion
treated with EMR is limited. However, a similar management strategy to that of flat LGD can be considered. BO; Barrett’s oesophagus, EMR; Endoscopic
mucosal resection, GI; Gastrointestinal, LGD; Low grade dysplasia, RFA; Radiofrequency ablation, HGD; High grade dysplasia, MDT; Multidisciplinary
team, OAC; Oesophageal adenocarcinoma, sm; submucosa.
8 W.K. Tan et al. / EJSO xx (2017) 1e13containing a bipolar electrode array which delivers thermal
energy onto targeted tissue. RFA can be delivered by
circumferential ablation (Halo360 system) or focal ablation
(Halo90 system). A RCT comparing RFA versus sham-
therapy for dysplasia showed that RFA was associated
with lower rate of dysplastic progression (3.6% vs 16.3%,
p ¼ 0.03) and cancer development (1.2% vs 9.3%,
p ¼ 0.045) than controls with a good safety profile.80
RFA was also associated with complete eradication of
LGD in 90.5% versus 22.7% in the sham-controlled group
(p < 0.001).80 More recently, a RCT which compared RFA
versus surveillance for LGD showed that RFA led to 25%
reduction in risk of progression to HGD/IMC.81 Results
from these trials have led to the BSG, ACG and BOBCAT
consensus recommending RFA for treating LGD.32,34,36
For HGD or IMC, nodular lesions should be removed
with endoscopic mucosal resection (EMR) followed by
RFA of remaining BO32 (Fig. 4). RFA post-EMR isPlease cite this article in press as: Tan WK, et al., Past, present and future of B
j.ejso.2017.02.004recommended as the risk of developing metachronous
neoplasia within 5 years after EMR is 14.5%.82 A recent
study also reported favourable outcomes for eliminating re-
sidual BO using a modified Argon Plasma Coagulation
(APC, an ablative technique using ionized argon gas) sys-
tem.83 Patients with residual BO 1 cm post-EMR for
early neoplasia were treated with Hybrid-APC (fluid injec-
tion into submucosa before ablation) and achieved histolog-
ical remission of BO in 78% (39/50) of cases.83
For neoplasia staged as T1b (invasion into submucosa),
oesophagectomy is preferred since up to 22% of submuco-
sal tumour will inherently have regional lymph node metas-
tases.84 However, poor surgical candidates with stage T1b
sm1 tumour (invasion of submucosa but confined to upper
3rd submucosal layer within 500 mm) but with low risk
tumour profile (well differentiated tumour without lympho-
vascular invasion); endoscopic therapy can be offered as an
alternative.85,86 The current BSG recommendations forarrett’s oesophagus, Eur J Surg Oncol (2017), http://dx.doi.org/10.1016/
Table 2
Comparison between BSG, ACG and BOBCAT consensus on the management of Barrett’s oesophagus.
Degree of dysplasia at index endoscopy British Society of Gastroenterology
(BSG)32
American College of
Gastroenterology (ACG)34
International consensus (BOBCAT)36
No dysplasia - Evaluate patient fitness and obtain
informed consent
- BO length <3 cm without IM:
Repeat OGD and if IM absent,
consider discharge
- BO length <3 cm with IM: OGD
in 3e5 years
- BO length 3 cm: OGD every 2e3
years
- Evaluate patient fitness and
obtain informed consent
- Repeat OGD with biopsy in
3e5 years
- Routine surveillance not recom-
mended, but if undertaken, it
should be targeted at high risk pa-
tients of which risk stratifications is
based on age, sex, BO length,
central obesity, duration, frequency
and severity of symptoms, smoking
status (influence of IM on surveil-
lance is unclear)
- No surveillance if life expectancy
<5 years
Indefinite for dysplasia Confirmation by 2 GI pathologists.
Optimize PPI, and repeat OGD in 6
months
Confirmation by 2 GI
pathologists. Optimize PPI and
repeat OGD (interval not
specified)
Confirmation by 2 GI pathologists.
Optimize PPI, and repeat OGD
within 12 months
LGD Flat mucosa Optimize PPI and repeat OGD in 6
months. If repeat OGD confirms
LGD (by 2 GI pathologist) offer
RFA. If RFA not undertaken, then 6-
monthly surveillance is
recommended
Optimize PPI and repeat OGD
(interval not specified). If repeat
OGD confirms LGD (by 2 GI
pathologist) offer RFA. If RFA
not undertaken, then yearly
surveillance
Optimize PPI and repeat OGD in
6e12 months. If repeat OGD
confirms LGD (by 2 GI pathologist)
offer RFA.
Nodular EMR to obtain optimal
histopathological staging. If LGD
confirmed, offer RFA of remaining
BO or 6 monthly surveillancea
EMR to obtain optimal
histopathological staging. If LGD
confirmed, offer RFA of
remaining BO or 6 monthly
surveillanceb
EMR to obtain optimal
histopathological staging. If HGD or
IMC present, offer RFA of remaining
BO
HGD or T1a stage (IMC) Flat mucosa Confirmation by 2nd GI pathologist.
If HGD confirmed, then RFA
Confirmation by 2nd GI
pathologist. If HGD confirmed,
then RFA
Confirmation by 2nd GI pathologist.
If HGD confirmed, then RFA97
Nodular EMR of nodule. If histopathological
confirmation of HGD/IMC, then
RFA of remaining BO epithelium
EMR of nodule. If
histopathological confirmation of
HGD/IMC, then RFA of
remaining BO epithelium
EMR of nodule. If histopathological
confirmation of HGD/IMC, then
RFA of remaining BO epithelium97
OAC T1b sm1 Oesophagectomy is preferred. If poor
surgical candidates, EMR þ RFA can
be considered if low risk tumour
profile
Oesophagectomy is preferred. If
poor surgical candidates,
EMR þ RFA can be considered if
low risk tumour profile
Oesophagectomy is preferred. If poor
surgical candidates, EMR þ RFA can
be considered if low risk tumour
profile97
T1b sm2 Oesophagectomy Oesophagectomy Oesophagectomy
LGD; Low grade dysplasia, HGD; High grade dysplasia, IMC; Intramucosal carcinoma, OAC; oesophageal adenocarcinoma OGD; oesophagogastroduode-
noscopy, BO; Barrett’s oesophagus, RFA; Radiofrequency ablation, GI; Gastrointestinal.
a There is limited data and no optimal recommendation regarding the management of LGD diagnosed on EMR specimens of nodular BO. However, a
similar management strategy to that of flat LGD should be considered.
b The ACG recommendation for LGD diagnosed on nodular EMR specimens of nodular BO is based on expert opinion only due to the paucity of data
surrounding this clinical entity.
9W.K. Tan et al. / EJSO xx (2017) 1e13HGD, T1a and T1b tumours are similar to that of the ACG
and BOBCAT consensus.34,36
Future therapeutic options for Barrett’s oesophagus
EMR and RFA combination have proven to be a highly
effective treatment for dysplastic BO; however, cryotherapy
is a new technology which is being evaluated. Here, we also
discuss the possible role of chemoprevention in BO.CryotherapyCryotherapy involves the use of a cryogen, usually
liquid nitrogen or cold carbon dioxide (CO2) to inducePlease cite this article in press as: Tan WK, et al., Past, present and future of B
j.ejso.2017.02.004tissue damage. The CryoSpray Ablation device (CSA Med-
ical) allows endoscopic delivery of liquid nitrogen while
the Polar Wand (GI Supply) and Coldplay cryoballoon sys-
tem (C2 Therapeutics/Pentax Medical, Fig. 2) delivers cold
CO2. Both systems cause freezing and thawing of Barrett’s
mucosa, resulting in apoptosis and subsequent sloughing of
dead epithelial followed by regrowth of neo-squamous
epithelial.87 Early data for cryotherapy has demonstrated
it to be safe and effective, achieving up to 87% eradication
of all forms of dysplasia (97% for HGD), and 3% stricture
rate which were easily treated with balloon dilation.88 More
recently Canto et al. also showed high success rate for erad-
ication of HGD with CO2 therapy (Cryoballoon), achieving
94% eradication at 1 year follow-up, with better success forarrett’s oesophagus, Eur J Surg Oncol (2017), http://dx.doi.org/10.1016/
10 W.K. Tan et al. / EJSO xx (2017) 1e13treatment na€ıve patients than as rescue therapy for those
treated unsuccessfully with other forms of ablative therapy
(100% vs 91%, respectively).89 Despite promising results
for cryotherapy, larger trials with direct comparison to
RFA are necessary prior to adopting this procedure into
clinical practice.Role of chemopreventionIn BO, prolonged gastric acid reflux can lead to DNA
strand breaks, oxidative damaged and increased cellular
proliferation, processes which could promote
carcinogenesis.90e92 A recent prospective cohort study
which investigated 540 patients with known BO with a
median 5.2 years follow-up showed that proton-pump in-
hibitors (PPI), but not Histamine-2 receptor antagonist,
was associated with a 79% decreased cancer risk
(HR ¼ 0.21, 95% CI 0.07e0.66).93 More recently, a
meta-analysis of 7 studies with >2800 patients showed
that PPI was associated with 71% reduction in cancer
risk (adjusted OR 0.29; 95% CI 0.12e0.79).94 Interest-
ingly however, a population based study of 9883 Danish
patients with a median 10.2-year follow-up showed no
protective effect of PPI on the incidence of HGD or
OAC.95 In fact, this study showed that longer-term use
of PPI was associated with higher risk of HGD or
OAC.95 As the role of PPI as a chemopreventive agent
is not well substantiated, established guidelines has only
recommended PPI to be used for symptomatic control
only.32,34,36
There has been some indirect evidence that aspirin or
other non-steroidal anti-inflammatory (NSAIDs) has a che-
mopreventive role. A pooled analysis of observational
studies showed a 40% reduction in cancer risk among pa-
tients taking aspirin or other NSAIDS.96 However, even if
there is a true reduction, its use may be offset by the poten-
tial for an increased risk of GI or intracranial haemorrhage.
Current societal guidelines do not recommend routine use
of aspirin/NSAIDs as chemoprevention for OAC due to
its potential side effects and the lack of level-1 evidence.
However, the AspECT trial, a RCT designed and powered
to assess the benefits of high or low-dose PPI with or
without aspirin in reducing risk of OAC in BO has recently
completed recruitment, and the results of this study are
awaited.
Conclusion
There have been significant advances in the field of BO
not only in diagnosis, but also in the different endoscopic
imaging and therapeutic modalities for BO. Although mi-
nor variations between the BSG, ACG and BOBCAT state-
ments exist, these societal recommendation do achieve
consensus in many domains, such as the reporting of BO
(Prague C&M criteria) and IM, endoscopic landmarks,
diagnosis and grading of dysplasia, and treatment strategiesPlease cite this article in press as: Tan WK, et al., Past, present and future of B
j.ejso.2017.02.004for dysplastic Barrett’s. Currently, surveillance forms the
mainstay of BO management with surveillance intervals
varying depending on the grade of dysplasia. However,
the future of surveillance in BO is gradually migrating to-
wards risk stratifying those at higher risk for cancer pro-
gression based on risk factors and biomarkers in order to
prioritise those patients with highest risk for cancer with
endoscopic therapy. Finally, in order to diagnose more
BO and have any chance of reducing the population mortal-
ity from OAC a better strategy for diagnosis in primary care
is required. The development of novel tests such as the
Cytosponge-TFF3 test, capsule-tethered VLE, and trans-
nasal endoscopy are an important step toward achieving
this goal.
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